Closing in on Cancer

Every Day.

Cancer is a devastating disease, but we’re up to the challenge and unwavering in our determination. Every day, we’re moving ahead in our mission to close in on cancer, by discovering and developing leading-edge, targeted treatments to address the unmet needs of patients with various types of cancer.

Our innovative multispecific Multiclonic® antibody therapeutics are engineered with compelling target combinations to work against the complex mechanisms that drive cancer. At the forefront of our pipeline is petosemtamab, a novel bispecific antibody with promising interim clinical results for head and neck cancer.


Our Multiclonics® therapeutics are full-length human IgG bispecific (Biclonics®) and trispecific (Triclonics®) antibodies that bind to multiple targets, and are manufactured with advantageous features for anti-cancer effects against the complex mechanisms that drive cancer. Multiclonics® are capable of being developed with industry standard processes and have been observed in preclinical studies to have similar features as conventional monoclonal antibodies, such as long half-life and low immunogenicity.


Our therapeutic candidates engage cancer antigens and harness the power of the immune system to kill tumor cells in unique and powerful ways by utilizing our proprietary technology platform and deep expertise in oncology. We are currently developing a broad pipeline of wholly owned and licensed Biclonics® drug candidates in the clinic with compelling target combinations and unique mechanisms of action.


Our lead cancer drug candidate is petosemtamab, a Biclonics® antibody targeting EGFR and LGR5. Petosemtamab has shown encouraging single agent clinical activity in previously treated head and neck cancer, and in combination with pembrolizumab in first line head and neck cancer, both areas of significant unmet medical need. An evaluation of petosemtamab in combination with standard chemotherapy in 2L colorectal cancer is ongoing.